Phase II trial of methylglyoxal-bis (guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: An eastern cooperative oncology group (ECOG) study

Jane N. Winter; Paul S. Ritch; Steven T. Rosen; Martin M. Oken; Janet M. Wolter; Peter H. Wiernik; Michael J. O'connell

doi:10.3109/07357909009017559

Phase II trial of methylglyoxal-bis (guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: An eastern cooperative oncology group (ECOG) study

Jane N. Winter^*, Paul S. Ritch, Steven T. Rosen, Martin M. Oken, Janet M. Wolter, Peter H. Wiernik, Michael J. O'connell

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m² was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m² on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.

Original language	English (US)
Pages (from-to)	143-146
Number of pages	4
Journal	Cancer Investigation
Volume	8
Issue number	2
DOIs	https://doi.org/10.3109/07357909009017559
State	Published - 1990

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/07357909009017559

Cite this

@article{13631c99395449629df34e83afc897b7,

title = "Phase II trial of methylglyoxal-bis (guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: An eastern cooperative oncology group (ECOG) study",

abstract = "Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.",

author = "Winter, {Jane N.} and Ritch, {Paul S.} and Rosen, {Steven T.} and Oken, {Martin M.} and Wolter, {Janet M.} and Wiernik, {Peter H.} and O'connell, {Michael J.}",

note = "Funding Information: (Paul P. Carbone, M.D., chairman,C A21115) a d supportedby Public Health Service grants from the NCI, National Institutes of Health, and the Department of Health and Human Services. Other participating institutions include Johns Hopkins Oncology Center, Baltimore, MD (CA 16116).",

year = "1990",

doi = "10.3109/07357909009017559",

language = "English (US)",

volume = "8",

pages = "143--146",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Phase II trial of methylglyoxal-bis (guanylhydrazone) (MGBG) in patients with refractory multiple myeloma

T2 - An eastern cooperative oncology group (ECOG) study

AU - Winter, Jane N.

AU - Ritch, Paul S.

AU - Rosen, Steven T.

AU - Oken, Martin M.

AU - Wolter, Janet M.

AU - Wiernik, Peter H.

AU - O'connell, Michael J.

N1 - Funding Information: (Paul P. Carbone, M.D., chairman,C A21115) a d supportedby Public Health Service grants from the NCI, National Institutes of Health, and the Department of Health and Human Services. Other participating institutions include Johns Hopkins Oncology Center, Baltimore, MD (CA 16116).

PY - 1990

Y1 - 1990

N2 - Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.

AB - Twenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2 was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2 on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.

UR - http://www.scopus.com/inward/record.url?scp=0025147138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025147138&partnerID=8YFLogxK

U2 - 10.3109/07357909009017559

DO - 10.3109/07357909009017559

M3 - Article

C2 - 2205334

AN - SCOPUS:0025147138

SN - 0735-7907

VL - 8

SP - 143

EP - 146

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

Phase II trial of methylglyoxal-bis (guanylhydrazone) (MGBG) in patients with refractory multiple myeloma: An eastern cooperative oncology group (ECOG) study

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this